Prohost Letter #453
Still Way UNDERVALUED
Finally, many analysts who happened to downgrade Gilead Science’s (GILD) stock for years are upgrading it.
Demonstrating time and time again its scientific genius in saving millions of people from deadly diseases, Gilead has, at long last, convinced the bearish analysts to turn bullish . . .
This content is for paid subscribers.
Prohost Letters December 29, 2022